Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Acq. completed
CC transcript
Director departure
BIO-RAD LABORATORIES, INC. (BIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/27/2011 BW BioAlliance Pharma Submits a Phase III Clinical Trial Application for Livatag® (doxorubicin Transdrug™) to the French Drug Agency (Afssaps)
06/24/2011 BW BioAlliance Pharma Submits Application for Orphan Medicinal Product Designation for Clonidine Lauriad™ in Europe and the United States
05/30/2011 BW A new Chief Executive Officer to strengthen BioAlliance Pharma's growth
05/25/2011 BW BioAlliance Pharma: Combined Ordinary and Extraordinary General Meeting on June 29th 2011
05/20/2011 BW Board Evolution at BioAlliance Pharma to Support Its Growth Strategy
05/16/2011 BW BioAlliance Pharma announces that Therabel launches Loramyc® in Germany with the support of Hikma
05/13/2011 BW Q1 2011: achievement of key milestones in BioAlliance Pharma's clinical development program
05/11/2011 BW BioAlliance Pharma expands its Loramyc® franchise in Japan with Sosei in a deal valued up to 18.5M$
04/27/2011 BW BioAlliance Pharma Accelerates Its European Clinical Development of Clonidine Lauriad™
03/31/2011 BW BioAlliance Pharma: Livatag® (Doxorubicin Transdrug™) Follow up Demonstrates Significant Survival Increase in Advanced Hepatocellular Carcinoma Patients
03/03/2011 BW BioAlliance Pharma Receives €2 Million in Funding for Peptide Applications of the Patented LauriadTM Mucoadhesive Technology
03/03/2011 BW BioAlliance Pharma: Full-Year Financial Results for 2010
02/10/2011 BW BioAlliance Pharma: Consolidated Turnover for 2010 Exceptional Performance Linked to International Licensing Agreements
12/15/2010 BW Bioalliance Pharma Announces New Opportunities for Its Patented Lauriad™ Mucoadhesive Technology
11/23/2010 BW BioAlliance Pharma Presents Preclinical and Phase I Clinical Results with Its AMEP® Biotherapy for Metastatic Melanoma
10/21/2010 BW The Structure of BioAlliance Pharma's Turnover for Q3 2010 Reflects the Dynamism of the Company's American and European Collaborations
10/19/2010 BW Dismissal of the civil action filed by Eurofins against BioAlliance in the United States confirmed by the US court of appeals
08/26/2010 BW BioAlliance Pharma: Acyclovir Lauriad®: US registration file submission planned end-2011
08/25/2010 BW BioAlliance Pharma SA: Consolidated Accounts for the First Semester of 2010
08/24/2010 BW BioAlliance Pharma Announces the Launch of Oravig® on the US Market by Its Commercial Partner, Strativa/Par Pharmaceutical
08/04/2010 BW Changes on BioAlliance Pharma General Management
07/22/2010 BW BioAlliance Pharma SA: A Record Turnover for Q2 2010 Reflecting the Successful US FDA Approval
07/01/2010 BW BioAlliance Pharma SA: Acyclovir Lauriad®: European Registration File Submission Planned for Mid-2011
06/28/2010 BW BioAlliance Pharma Presents Phase III Results with Loramyc® (Miconazole Lauriad®) and Ongoing Phase II Trial with Clonidine Lauriad®
04/26/2010 BW BioAlliance Pharma SA: April 22nd 2010 General Assembly Meeting: Equity investment by Therabel and transition from a Supervisory Board to a Board of Directors
04/22/2010 BW BioAlliance Pharma SA: Q1 2010 reflects the new European partnership agreement with Therabel
04/16/2010 BW BioAlliance Pharma Gains US FDA Approval for Oravig® (Loramyc® in EU)
04/06/2010 BW BioAlliance Pharma Announces Licensing of European Commercialization Rights for Loramyc® and Setofilm® to the Therabel Group in a €48.5 Million Deal
03/25/2010 BW BioAlliance Pharma Announces Extension of Loramyc® Approval in 13 European Countries
03/23/2010 BW Bioalliance Pharma Receives European Approval for Its Second Innovative Product Setofilm®
03/03/2010 BW CORRECTING AND REPLACING BioAlliance Pharma SA: Full-year accounts for 2009
02/09/2010 BW BioAlliance Pharma Announces Its Consolidated Turnover for 2009 a Doubling in Recurring Revenues

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy